Arbutus Biopharma
ABUS
ABUS
111 hedge funds and large institutions have $152M invested in Arbutus Biopharma in 2023 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 38 increasing their positions, 30 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
9% less funds holding
Funds holding: 122 → 111 (-11)
19% less capital invested
Capital invested by funds: $189M → $152M (-$36.9M)
45% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 22
Holders
111
Holding in Top 10
3
Calls
$2.34M
Puts
$1.13M
Top Buyers
| 1 | +$4.77M | |
| 2 | +$3.46M | |
| 3 | +$1.88M | |
| 4 |
WCM
Whitefort Capital Management
New York
|
+$1.37M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$713K |
Top Sellers
| 1 | -$1.84M | |
| 2 | -$1.51M | |
| 3 | -$848K | |
| 4 |
Two Sigma Investments
New York
|
-$709K |
| 5 |
JPMorgan Chase & Co
New York
|
-$435K |